- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Shalby Limited — PPTs, 13-08-2025: Investor Presentation
**Financial Highlights:**
Shalby's Q1 FY26 consolidated revenue rose 5.1% YoY to ₹303.4 Cr. However, EBITDA declined 11.6% to ₹48.5 Cr, leading to PBT dropping 25.5% to ₹22.7 Cr and PAT falling 47.9% to ₹7.7 Cr. Standalone revenue saw a modest 0.7% increase to ₹242.2 Cr, with EBITDA dipping 9.8% to ₹52.4 Cr. Hospital occupancy was 45% (down from 48%), though ARPOB improved 5.3%. Consolidated net debt stood at ₹302.5 Cr. The implant business, Shalby MedTech (consolidated), surged 74.2% in revenue to ₹30.83 Cr, significantly reducing its EBITDA loss.
**Strategic Initiatives & Growth Drivers:**
The company is expanding through an asset-light franchise model and diversifying services beyond joint replacements into cardiac, oncology, neuroscience, and transplants. Growth is also anticipated from homecare and international business expansion. Shalby aims to scale its US FDA-approved implant manufacturing to a USD 100 Mn global business, focusing on prudent capital allocation and doubling ROCE.
**Business Developments:**
Shalby achieved a major milestone by performing the world's first fully autonomous robotic joint replacement surgery. The quarter also saw successful complex surgeries and 25 transplants. Shalby Academy enrolled over 630 new students, strengthening its healthcare training initiatives.
**Market Position & Competitive Advantage:**
Shalby maintains its global leadership in joint replacements, with over 175,000 surgeries performed. It is a dominant corporate hospital group in Western and Central India, operating 15 hospitals. Its US-based implant manufacturing facility provides a distinct competitive edge.
**Investor Implications:**
While profitability faced margin compression, revenue growth and strong implant business performance suggest underlying potential. The strategic focus on asset-light models, diversification, and global implant expansion offers avenues for future growth. Investors should monitor operational efficiency improvements for enhanced profitability.